Nothing Phone 3 Is Coming to the US—But Not to Carriers
A close-up of the Nothing Phone's signature transparent rear, showcasing its minimalist design and dual-camera layout.
The innovative Android handset Nothing Phone 3 is coming to US and Canadian shores soon via Amazon and Best Buy, respectively.
As originally reported by TechCrunch and confirmed by Nothing CEO Carl Pei on X, the Nothing Phone 3 stands out in a sea of sameness. Its unique LED notifications on the back of the phone are useful and interesting to look at.
Unlike many phones, though, the Nothing Phone 3 won't be at your local AT&T, Verizon, or T-Mobile shop. You'll buy the handset via Amazon or Nothing.com here in the states, or Best Buy up in Canada. What that implies is an unlocked phone, much like the Nothing Phone 2 was. — Nothing (@nothing) May 20, 2025
Nothing was founded in 2020 by Carl Pei, the previous co-founder of OnePlus. Its first big release was the Nothing Ear (1) a set of wireless earbuds with a distinctive see-through design. Nothing's Phone (1) came out in 2022, showing off a transparent design and a new Glyph interface that uses the rear case to notify you of calls and texts visually. The Nothing Phone 2 arrived in 2023 and took the design to a new level with an integrated theme as its interface. The 3(a) Pro continued improving design and camera features while adding AI functions, keeping the price low while doing so.
While there's no new pricing info, TechCrunch notes that Pei said the Nothing Phone 3 should come in at around $1,000 US, putting it in direct competition with iPhone 16 Pro and Samsung Galaxy S25+.
As Apple and Samsung (and OnePlus) continue to iterate their new phone offerings, it's interesting to see an alternative smartphone join the general US market, one that bets on its personality rather than looking like every other smartphone out there. Whether that translates to sales remains to be seen.
You can sign up for updates on the Nothing Phone (3) over at the Nothing website.
Originally published on Tech Times ⓒ 2024 TECHTIMES.com All rights reserved. Do not reproduce without permission.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Int'l Business Times
a day ago
- Int'l Business Times
Sahel Juntas Pile Pressure On Foreign Mining Firms
Army strongmen who have seized power in coups across Africa's Sahel region since 2020 have ramped up pressure on foreign mining companies in the name of greater control over their countries' riches. Niger's nationalisation of the local branch of French uranium giant Orano on Thursday is the latest such measure by the junta and its allies in Burkina Faso and Mali. In particular the coup-hit trio, which have all turned their backs on their shared former colonial master France in favour of stronger ties with Russia, have placed Western firms firmly in their sights. Niger's nationalisation of Orano's local branch Somair has brought a months-long struggle with the French firm to a peak. Orano, which is 90-percent owned by the French state, had already admitted to having lost operational control of its subsidiary months ago. Meanwhile in Mali, Canadian giant Barrick Mining is locked in a tug-of-war with the army over a mining code that came into force in 2023. The military is demanding hundreds of millions of dollars of back taxes from the firm. Barrick has since lost control of Loulo-Gounkoto, the country's largest gold mine, in which the Canadian firm holds a majority stake. In November 2024, Malian soldiers arrested the director of Australia's Resolute Mining, along with two employees. All were subsequently released after Resolute agreed to pay the junta $160 million in exchange. Other mine companies such as Canada's allied Gold, B2Gold and Robex had previously agreed to review their activities and pay to settle their tax or customs dispute. And in 2023 Burkina Faso seized 200 kilograms (440 pounds) of gold produced by a branch of Canada's Endeavour Mining on "public necessity" grounds. For the juntas, the point of the push against foreign mining companies is to reestablish sovereignty and control over their national resources. Where they believed the Sahel's resource riches were previously sold out to foreigners, and to the West in particular, today the army leaders promise their people that ordinary citizen will receive a greater share of the profits from the wealth under their feet. Niger produces nearly five percent of the world's uranium. Gold makes up a quarter of Mali's national budget. And Burkina Faso's gold production contributes around 14 percent of the country's revenues, according to official statistics. "The population sees this as a push to free states which were previously, according to the new authorities, subservient to Westerners and therefore foreign interests," said Jeremie Taieb, director of consulting firm Tikva Partners. This rejection therefore "helps to satisfy public opinion and nurtures a narrative that allows those in power to keep it", Taieb added. All three countries are plagued by jihadist violence, which has claimed thousands of lives across the region. Besides economic sanctions imposed on the juntas in the wake of the coups, "the pressures exerted to fund the fight against terrorism" provide as good a reason as any "to extract more income from the sector", said Beverly Ochieng, an analyst at Control Risks. To fight back against the juntas, the mining industry has looked to international arbitration. Barrick has turned to the International Centre for Settlement of Investment Disputes (ICSID), part of the Washington-based World Bank. France's Orano has launched various lawsuits against the state of Niger, accusing the junta of a "systematic policy of stripping mining assets". In a statement Friday evening, the day after Niger announced its intention to nationalise its subsidiary, the firm said it "intends to claim compensation for all of its damages and assert its rights over the stock corresponding to Somair's production to date". For Taieb, this "legal instability" in the Sahel could drive investors towards countries with a more reliable business backdrop. But for Control Risks' Ochieng, "foreign firms will probably continue to engage with administrations in the Sahel... as mining assets represent a hefty and long-term investment". In any case the countries that stand to gain most from the current climate are Mali, Niger and Burkina Faso's so-called "security partners" -- especially Turkey, China and Russia. On Monday, Mali and Russia began construction work on a new gold refinery in the Malian capital Bamako. Moscow has also sent mercenaries from its paramilitary Africa Corps to the Sahel country to help fight jihadists. For the Russians, the deal is "minerals for weapons, in the same way that for the Chinese, it's minerals for infrastructure", said Taieb.
Int'l Business Times
a day ago
- Int'l Business Times
Amazon's AI Revolution Brings Job Cut Warnings, Relocation Mandate Adds to Employee Uncertainty
Amazon, a global e-commerce and tech giant, which is on the cusp of an artificial intelligence revolution, is sparking significant concerns among its workforce. With whispers of impending job cuts and a recent mandate requiring some employees to relocate, a palpable sense of uncertainty is now hanging over Amazon's vast employee base. Amazon's AI Revolution: A Time of Unease for Employees Amazon CEO Andy Jassy has hinted at workforce reductions, attributing them to the rapid advancements in AI. He has confirmed that the company will require fewer employees as Amazon pursues greater efficiency with Generative AI. The severity of the situation, including how many roles will be cut, remains unconfirmed, but the message clearly tells employees to prepare themselves for upcoming layoffs. Jassy's note, also shared on his public blog, highlights AI's rapid progress and profound impact on business efficiency and operations. Furthermore, Bloomberg reports that Amazon is poised to announce these cuts next month. 'As we roll out more Generative AI and agents, it should change the way our work is done. We will need fewer people doing some of the jobs that are being done today, and more people doing other types of jobs,' Jassy wrote in his note to the employees. He added, 'It's hard to know exactly where this nets out over time, but in the next few years, we expect that this will reduce our total corporate workforce as we get efficiency gains from using AI extensively across the company.' Efficiency Driven by AI: A Changing Workforce Amazon claims to have developed over 1,000 Generative AI services, with additional applications under development. This year, the company pledged to invest $100 million in AI technologies. Jassy hailed AI as a 'one-in-a-lifetime technology,' stating it will reshape Amazon's operational approach. Beyond the impact of AI, Amazon's workforce is grappling with another pressing issue: a strict relocation policy that leaves many employees with a difficult choice. Forced Moves: The Relocation Ultimatum Citing sources familiar with the situation, Bloomberg reports that Amazon has issued an ultimatum to its corporate employees: move closer to their managers and teams or resign without any severance. Amazon requires employee relocation: No severance offered via My Northwest local news feed. This is really interesting, and a sign of things to come at other companies. AI means fewer employees, which means Corporate will start demanding 'do this or goodbye' workforce… — stevemur (@stevemur) June 20, 2025 According to the report, employees must relocate to key centres, including Seattle, Arlington (Virginia), and Washington, D.C., a mandate that may necessitate cross-country moves for many. Employee Concerns Mount Amidst Changes This policy has sparked fresh concern among Amazon employees, who are already uneasy due to ongoing job reductions and warnings that AI might diminish their roles in the years ahead. A source cited by Bloomberg suggests this new directive could impact thousands of employees across different teams, particularly mid-career staff reluctant to move because of family commitments and spousal careers. The 30-Day Relocation Mandate The company operates numerous satellite offices throughout the US, including in key cities such as New York, Boston, Los Angeles, and Austin. These locations have typically offered employees some choice in where they reside. One employee revealed to Bloomberg that this message was given during a team meeting. Their manager reportedly informed them they had 30 days to decide on relocating. Should they opt against it, they would receive 60 days to resign or start the relocation process. The manager said, ' There would be no severance for employees who resigned in lieu of relocating.' Originally published on IBTimes UK This article is copyrighted by the business news leader
Int'l Business Times
3 days ago
- Int'l Business Times
Passion, Plants, and Phase III: Devonian Health Group Is on a Mission to Disrupt Inflammation Therapy
While the industry might be dominated by synthetic compounds, billion-dollar VC funds, and long, uncertain development timelines, Devonian Health Group Inc. is proving there is another way. As a publicly traded company, under the leadership of its founder and CEO, Dr. André P. Boulet, Devonian has quietly advanced multi-target drug candidates and a cutting-edge cosmeceutical line, backed not by institutional investors but by a network of Canadian family offices made up of dentists, physicians, engineers, and entrepreneurs. Boulet's journey to this unconventional success story reads like a masterclass in risk, reinvention, and scientific conviction. "I'm a venture capitalist in my heart," Boulet says. "But I'm also a scientist. When I saw the anti-inflammatory results of this botanical extract technology from a university agriculture project, I knew this had real potential. So, I followed my instinct and took the risk." With a PhD in physiology-endocrinology, postdoctoral training in biochemistry and biophysics, and experience leading cardiovascular clinical research programs, Boulet's transition from academia to venture capital was swift. After climbing the pharmaceutical ladder and managing funds in Montreal, he exited his partnership and launched what would become Devonian Health Group in 2015. At its core, Devonian is a clinical-stage pharmaceutical company focused on autoimmune and inflammatory conditions, with its lead drug candidate, Thykamine ™, poised to enter Phase III clinical trials for atopic dermatitis and soon pediatric eczema. "Traditional pharma was built on the 'silver bullet,' one target, one mechanism," Boulet explains. "But now science is evolving. We're moving toward therapies that modulate multiple pathways. That's exactly what Thykamine does without shutting down important immune functions like TNF-alpha. That's why our efficacy is high, but side effects are minimal." What sets Devonian apart isn't just its marquee drug but the platform behind it. The company's patented SUPREX™ technology allows for water-based extraction, purification, and stabilization of Active Botanical Ingredients (ABIs) from plants and algae. These complexes modulate inflammation at the genetic level across multiple diseases, offering a broad pipeline of possibilities. To date, Thykamine™ has demonstrated strong results in its Phase II trial. Both gastrointestinal (ulcerative colitis) and dermatological (eczema) models have shown significant symptom relief and safety comparable to placebo. Remarkably, all this has been achieved without traditional VC backing. Boulet credits this to his deep network of entrepreneurial allies and his belief in business-first partnerships. "We've raised funds to advance to Phase III, built an extraction and production facility, and kept the company debt-free," he says. While the pharmaceutical arm garners headlines, Devonian's cosmeceutical division is equally ambitious. Operating under the Purgenesis™ brand, the company has developed a premium line of anti-aging creams containing its patented botanical ingredient R-Spinasome®, a photosynthetic cell extract with dynamic antioxidant properties. What makes Purgenesis™ unusual in the beauty space is its clinical rigor. Devonian has conducted peer-reviewed, pharma-grade clinical trials on the entire product line, something virtually unheard of in the cosmeceutical industry. "We've scientifically proven a reduction in wrinkles," says Boulet. "Not just pretty pictures, but peer-reviewed, published data. We're the only ones doing cosmeceuticals the pharma way." With day, night, and eye creams already developed and a professional-grade serum in the pipeline, Devonian is currently seeking commercial partners to bring Purgenesis™ to a global market hungry for results-backed skincare. Perhaps the most unusual aspect of Devonian's success is how personal it all feels. There are no Silicon Valley investors or hedge fund suits behind the curtain, just a network of entrepreneurs who believe in the mission. "Working with family offices is stimulating," Boulet says. "You get input from pharmacists, dentists, and industrialists. We face challenges together, and we have fun doing it." The company's headquarters in Québec includes a full-scale extraction and production facility, providing complete traceability from seed to pill. This vertical integration helps with both cutting costs, yes, but also ensuring product consistency. For Boulet, the journey has been one of passion and perseverance. "In life, there's always a risk," he reflects. "But if you surround yourself with the right people and believe in what you're building, that risk becomes your fuel. That's what Devonian is about: science, instinct, and community." As the company readies for Phase III trials in both pharmaceuticals and final-stage commercialization of its skincare line, Devonian Health Group stands as a testament to the power of conviction and the potential of plants to reshape the future of medicine.
